BIOMAT Database Logo BIOMAT Database Logo

Acute neuromuscular failure related to long-term botulinum toxin therapy. 2004

Mario Coletti Moja, and Ugo Dimanico, and Tiziana Mongini, and Valentina Cavaciocchi, and Pier Carlo Gerbino Promis, and Enzo Grasso
Department of Neurology, S. Croce Hospital, Cuneo, Italy. neurologia@sanluigi.piemonte.it

UI MeSH Term Description Entries
D008297 Male Males
D009465 Neuromuscular Agents Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS. Skeletal Muscle Relaxants,Neuromuscular Effect,Neuromuscular Effects,Agents, Neuromuscular,Effect, Neuromuscular,Effects, Neuromuscular,Muscle Relaxants, Skeletal,Relaxants, Skeletal Muscle
D009468 Neuromuscular Diseases A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA. Amyotonia Congenita,Oppenheim Disease,Cramp-Fasciculation Syndrome,Fasciculation-Cramp Syndrome, Benign,Foley-Denny-Brown Syndrome,Oppenheim's Disease,Benign Fasciculation-Cramp Syndrome,Benign Fasciculation-Cramp Syndromes,Cramp Fasciculation Syndrome,Cramp-Fasciculation Syndromes,Fasciculation Cramp Syndrome, Benign,Fasciculation-Cramp Syndromes, Benign,Foley Denny Brown Syndrome,Neuromuscular Disease,Oppenheims Disease,Syndrome, Cramp-Fasciculation,Syndrome, Foley-Denny-Brown,Syndromes, Cramp-Fasciculation
D011729 Pyridostigmine Bromide A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. Mestinon,Pyridostigmine,Bromide, Pyridostigmine
D011782 Quadriplegia Severe or complete loss of motor function in all four limbs which may result from BRAIN DISEASES; SPINAL CORD DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; NEUROMUSCULAR DISEASES; or rarely MUSCULAR DISEASES. The locked-in syndrome is characterized by quadriplegia in combination with cranial muscle paralysis. Consciousness is spared and the only retained voluntary motor activity may be limited eye movements. This condition is usually caused by a lesion in the upper BRAIN STEM which injures the descending cortico-spinal and cortico-bulbar tracts. Quadriparesis,Spastic Quadriplegia,Tetraplegia,Flaccid Quadriplegia,Flaccid Tetraplegia,Paralysis, Spinal, Quadriplegic,Spastic Tetraplegia,Flaccid Quadriplegias,Flaccid Tetraplegias,Quadripareses,Quadriplegia, Flaccid,Quadriplegia, Spastic,Quadriplegias,Quadriplegias, Flaccid,Quadriplegias, Spastic,Spastic Quadriplegias,Spastic Tetraplegias,Tetraplegia, Flaccid,Tetraplegia, Spastic,Tetraplegias,Tetraplegias, Flaccid,Tetraplegias, Spastic
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Mario Coletti Moja, and Ugo Dimanico, and Tiziana Mongini, and Valentina Cavaciocchi, and Pier Carlo Gerbino Promis, and Enzo Grasso
Long-term effects of botulinum toxin on neuromuscular function.
June 2007, Anesthesiology,
Mario Coletti Moja, and Ugo Dimanico, and Tiziana Mongini, and Valentina Cavaciocchi, and Pier Carlo Gerbino Promis, and Enzo Grasso
Botulinum toxin in long-term therapy for achalasia.
April 1998, Annals of internal medicine,
Mario Coletti Moja, and Ugo Dimanico, and Tiziana Mongini, and Valentina Cavaciocchi, and Pier Carlo Gerbino Promis, and Enzo Grasso
[Long-term effects of botulinum toxin treatment].
May 2009, Annales de dermatologie et de venereologie,
Mario Coletti Moja, and Ugo Dimanico, and Tiziana Mongini, and Valentina Cavaciocchi, and Pier Carlo Gerbino Promis, and Enzo Grasso
[Antibody-induced failure of botulinum toxin therapy].
December 2003, Der Nervenarzt,
Mario Coletti Moja, and Ugo Dimanico, and Tiziana Mongini, and Valentina Cavaciocchi, and Pier Carlo Gerbino Promis, and Enzo Grasso
Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
August 2003, Journal of neurology,
Mario Coletti Moja, and Ugo Dimanico, and Tiziana Mongini, and Valentina Cavaciocchi, and Pier Carlo Gerbino Promis, and Enzo Grasso
[Neuromuscular blockade with botulinum toxin. From toxin to therapeutic agent].
May 2001, MMW Fortschritte der Medizin,
Mario Coletti Moja, and Ugo Dimanico, and Tiziana Mongini, and Valentina Cavaciocchi, and Pier Carlo Gerbino Promis, and Enzo Grasso
Long-term botulinum toxin efficacy, safety, and immunogenicity.
May 2005, Movement disorders : official journal of the Movement Disorder Society,
Mario Coletti Moja, and Ugo Dimanico, and Tiziana Mongini, and Valentina Cavaciocchi, and Pier Carlo Gerbino Promis, and Enzo Grasso
Oromandibular dystonia: long-term management with botulinum toxin.
December 2013, The Laryngoscope,
Mario Coletti Moja, and Ugo Dimanico, and Tiziana Mongini, and Valentina Cavaciocchi, and Pier Carlo Gerbino Promis, and Enzo Grasso
[Botulinum toxin in infantile estropia: long-term results].
April 2004, Journal francais d'ophtalmologie,
Mario Coletti Moja, and Ugo Dimanico, and Tiziana Mongini, and Valentina Cavaciocchi, and Pier Carlo Gerbino Promis, and Enzo Grasso
Long-term safety of botulinum toxin type A.
September 2003, Movement disorders : official journal of the Movement Disorder Society,
Copied contents to your clipboard!